RxDoctor Payments Data

Stephanie Lowry, MD

Adolescent Medicine · Springdale, ARNPI 1962600312

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 44.2% of the total. Reporting peaked in 2022 at $450 and has fallen 85.0% since, to $68 in 2025.

$1,220in general payments, 2019–2025

Across 77 payments — averaging $15.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$540
  • Baxter Healthcare$98
  • Exeltis, USA Inc.$90
  • Bayer$74
  • Astellas Pharma US Inc$53
  • Hologic Sales And Service, LLC$50
  • plus $316 from 13 others

What the payments were for

  • Food & beverage$1,220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,220 in reported general payments places this provider in the 85th percentile of 20 adolescent medicine providers in Arkansas.

See all adolescent medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$10,051
Medicare patients
68
Services billed
108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Emgality PenGalcanezumab-Gnlm12$15,420
EliquisApixaban12$8,726
JanuviaSitagliptin Phosphate12$6,325
Carbamazepine ErCarbamazepine12$2,099
SynthroidLevothyroxine Sodium34$1,887
Levothyroxine Sodium170$1,074
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine23$967
Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol12$963
Gabapentin40$956
Omeprazole97$834
Bupropion XlBupropion Hcl38$659
Escitalopram Oxalate60$549
Losartan Potassium87$461
Atorvastatin Calcium114$438
Duloxetine Hcl37$404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$8,72612 claims
AbbVieSynthroid, Armour Thyroid$540$2,27046 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 20 adolescent medicine providers in Arkansas.

Other adolescent medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →